Abeona in-licenses PSMA T-cell therapy, deprioritizes ophthalmology

 

Abeona beats Q1 estimates with $0.30 loss per share and $8.7M revenue, in-licenses PSMA T-cell therapy, deprioritizes ophthalmology

• Q1 2026 revenue included $8.7M from ZEVASKYN, as previously disclosed in the company’s results update.
• The company in-licensed ABO-701, described as a novel PSMA-targeting T-cell therapy.
• Abeona deprioritized its ophthalmology programs as part of a broader strategic pipeline realignment.

https://finviz.com/quote?t=ABEO&p=d